Cambridge Investment Research Advisors’s AGF US Market Neutral Anti-Beta Fund BTAL Stock Holding History
Bought
Maintained
Sold
Other funds holding BTAL
FDCDDQ
OIA
CCA
KF
AWM
KAS
ASN
Cambridge Investment Research Advisors's BTAL Position: Q4 2025 in Review
Cambridge Investment Research Advisors sold out of AGF US Market Neutral Anti-Beta Fund (BTAL) in Q4 2025, closing a stake of 38,905 shares — an estimated $619K sold.
Cambridge Investment Research Advisors first reported a position in BTAL in Q4 2018 and held it in 12 quarters. The position peaked at $3.21M in Q3 2022. 81 funds tracked by Wall St. Rank hold BTAL as of Q4 2025.
- Cambridge Investment Research Advisors reported no remaining AGF US Market Neutral Anti-Beta Fund position as of Q4 2025 after selling out during the quarter.
- Cambridge Investment Research Advisors sold 38,905 AGF US Market Neutral Anti-Beta Fund shares in Q4 2025, an estimated $619K.
- Cambridge Investment Research Advisors first reported a position in AGF US Market Neutral Anti-Beta Fund in Q4 2018 and held it in 12 quarters.
- Cambridge Investment Research Advisors's AGF US Market Neutral Anti-Beta Fund position peaked at $3.21M in Q3 2022.
- 81 funds tracked by Wall St. Rank held AGF US Market Neutral Anti-Beta Fund as of Q4 2025.
Based on Cambridge Investment Research Advisors's 13F filing for Q4 2025, filed 5 Feb 2026.